Incannex Healthcare (NASDAQ:IXHL – Get Free Report) and Vaxart (NASDAQ:VXRT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, risk and earnings.
Earnings & Valuation
This table compares Incannex Healthcare and Vaxart”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Incannex Healthcare | $90,000.00 | 1,035.23 | -$46.88 million | ($0.59) | -0.46 |
| Vaxart | $47.40 million | 2.84 | -$66.95 million | ($0.23) | -2.43 |
Risk and Volatility
Incannex Healthcare has a beta of 7.46, meaning that its share price is 646% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Incannex Healthcare and Vaxart, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Incannex Healthcare | 1 | 0 | 0 | 0 | 1.00 |
| Vaxart | 0 | 0 | 1 | 0 | 3.00 |
Vaxart has a consensus target price of $2.00, suggesting a potential upside of 257.14%. Given Vaxart’s stronger consensus rating and higher probable upside, analysts clearly believe Vaxart is more favorable than Incannex Healthcare.
Insider and Institutional Ownership
0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 18.0% of Vaxart shares are owned by institutional investors. 1.3% of Incannex Healthcare shares are owned by insiders. Comparatively, 2.8% of Vaxart shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Incannex Healthcare and Vaxart’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Incannex Healthcare | N/A | -150.92% | -127.94% |
| Vaxart | -122.63% | -91.89% | -38.40% |
Summary
Vaxart beats Incannex Healthcare on 9 of the 14 factors compared between the two stocks.
About Incannex Healthcare
Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.
About Vaxart
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.
Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
